Valuation : Adaptive Biotechnologies Corporation

Market Cap 4.22B 3.62B 3.39B 3.11B 5.85B 403B 5.87B 40.16B 15.7B 203B 15.84B 15.5B 672B P/E 2026 *
-48.5x
P/E 2027 * -150x
Enterprise Value 4.16B 3.57B 3.34B 3.06B 5.77B 397B 5.78B 39.6B 15.48B 200B 15.62B 15.28B 663B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 11.5x
Free-Float
97.93%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week+3.93%
Current month+17.15%
1 month+17.30%
3 months+91.04%
6 months+65.04%
Current year+62.81%
1 week 25.09
Extreme 25.09
26.87
1 month 21.74
Extreme 21.74
26.87
Current year 12
Extreme 12
26.87
1 year 12
Extreme 12
26.87
3 years 2.28
Extreme 2.28
26.87
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/26 Fiscal year

Director

60,664 0.0379%
18/08/26 Fiscal year

Chief Executive Officer

836,028 0.5224%
17/08/26 Fiscal year

Director

154,690 0.0967%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%+3.93%+103.86%+329.22% 4.22B
+2.23%-8.12%+241.32%+34.31% 3.74B
+2.17%+8.28%+58.16%+77.94% 3.64B
+2.75%+11.43%+293.98%+499.77% 2.71B
-2.91%+4.01%-26.20%-20.95% 2.33B
-1.06%+3.18%+32.26% - 1.5B
-5.96%+0.97%+259.23%-19.52% 1.25B
-2.18%+3.80%+19.81%+45.60% 1.05B
+1.68%+22.01%+34.48%+180.72% 694M
+1.18%-0.41%-36.72%+4.06% 546M
Average -0.10%+5.83%+98.02%+125.68% 2.17B
Weighted average by Cap. +0.55%+4.30%+123.85%+161.45%

Financials

2026 *2027 *
Net sales 293M 252M 236M 216M 407M 28.01B 408M 2.79B 1.09B 14.12B 1.1B 1.08B 46.72B 359M 308M 288M 264M 497M 34.24B 498M 3.41B 1.33B 17.26B 1.35B 1.32B 57.12B
Net income -85.78M -73.63M -68.94M -63.12M -119M -8.19B -119M -816M -319M -4.13B -322M -315M -13.67B -27.55M -23.65M -22.14M -20.28M -38.19M -2.63B -38.3M -262M -102M -1.33B -103M -101M -4.39B
Net Debt -58.99M -50.64M -47.41M -43.41M -81.78M -5.63B -82.01M -561M -219M -2.84B -221M -217M -9.4B -104M -89.13M -83.45M -76.41M -144M -9.92B -144M -988M -386M -5B -390M -381M -16.54B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
27/08/26 $26.44 +1.07% 1,944,721
26/08/26 $26.16 -0.34% 1,387,277
25/08/26 $26.25 +2.74% 1,221,787
24/08/26 $25.55 -1.69% 1,694,427
21/08/26 $25.99 +2.16% 1,816,948
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
26.44USD
Average target price
25.07USD
Spread / Average Target
-5.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock